Download PDF
Arthritis und Rheuma 2023; 43(06): 375-386
DOI: 10.1055/a-2181-5003
Schwerpunkt

Behandlung therapierefraktärer Verläufe der polyartikulären JIA

Johannes-Peter Haas
1   Deutsches Zentrum für Kinder- und Jugendrheumatologie, Garmisch-Partenkirchen
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

ZUSAMMENFASSUNG

Als juvenile idiopathische Arthritis (JIA) wird eine Arthritis mit einer Dauer von mehr als 6 Wochen bezeichnet, wenn: (i) sie vor dem 16. Lebensjahr erstmalig auftritt und (ii) keine anderen Ursachen gefunden werden können. Aus heutiger Sicht lassen sich mindestens 4 Gruppen kindlicher rheumatischer Polyarthritis differenzieren: (a) die zumeist ANA-positiven, Rheumafaktor-negativen kindlichen Formen (eo-JIA und RF– pJIA), (b) die Rheumafaktor-positive Form mit Beginn im Kindes- und Jugendalter (RF+ pJIA), (c) eine polyartikuläre Verlaufsform der sJIA ohne Symptome systemischer Inflammation, (d) die monogenetisch bedingte Polyarthritis aufgrund einer LACC1/FAMIN-Mutation. Letztere ist damit eigentlich keine rheumatische, sondern eine hereditäre Polyarthritis. Ausgehend von den ProKind-Protokollen zur Therapie der polyartikulären JIA wird das Vorgehen bei Nichterreichen der angestrebten Therapieziele erarbeitet. Dies sind neben ausführlicher Diagnostik und Dokumentation der Aktivität die Einschätzung von Komorbiditäten (z. B. Infektionen), Medikamenteninteraktionen und Problemen der „Non-Compliance“ bzw. „Non-Adherence“. Neben Maßnahmen zur Therapie einer fortbestehenden lokalen therapierefraktären Aktivität werden systemische Therapieoptionen, insbesondere die neu verfügbaren Januskinase-Inhibitoren (JAKi), diskutiert.

Schlüsselwörter

Polyartikuläre juvenile idiopathische Arthritis - Treat-to-Target - therapierefraktäre JIA - Pro-KIND


Publication History

Article published online:
21 December 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Heiligenhaus A, Klotsche J, Niewerth M. et al Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany. Arthritis Res Ther 2020; 22: 81
    CrossrefPubMedSearch in Google Scholar
  • 2 Ramsey SE, Bolaria RK, Cabral DA. et al Comparison of criteria for the classification of childhood arthritis. J Rheumatol 2000; 27: 1283-1286
    PubMedSearch in Google Scholar
  • 3 Krumrey-Langkammerer M, Hafner R. Evaluation of the ILAR criteria for juvenile idiopathic arthritis. J Rheumatol 2001; 28: 2544-2547
    PubMedSearch in Google Scholar
  • 4 Bertilsson L, Andersson-Gare B, Fasth A. et al Disease course, outcome, and predictors of outcome in a population-based juvenile chronic arthritis cohort followed for 17 years. J Rheumatol 2013; 40: 715-724
    CrossrefPubMedSearch in Google Scholar
  • 5 Hugle B, Hinze C, Lainka E. et al Development of positive antinuclear antibodies and rheumatoid factor in systemic juvenile idiopathic arthritis points toward an autoimmune phenotype later in the disease course. Pediatr Rheumatol Online J 2014; 12: 28
    CrossrefPubMedSearch in Google Scholar
  • 6 Thomschke S, Schulz M, Bätzing J.. Epidemiologie der juvenilen idiopathischen Arthritis (JIA) in der ambulanten Versorgung – eine Analyse anhand bundesweiter vertragsärztlicher Abrechnungsdaten der Jahre 2009 bis 2015 (2018). In: Versorgungsatlas.de. Zentralinstitut für die kassenärztliche Versorgung in Deutschland (Zi), Berlin. 1-16
  • 7 Martini A, Ravelli A, Avcin T. et al Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. J Rheumatol 2019; 46: 190-197
    CrossrefPubMedSearch in Google Scholar
  • 8 Lainka E, Haas JP, Horneff G. et al Systemic Juvenile Idiopathic Arthritis – New Aspects of Clinical Features, Diagnostic Tools and Treatment Strategies. Ann Paediatr Rheumatol 2013; 02: 3-13
    CrossrefSearch in Google Scholar
  • 9 Weiss PF, Xiao R, Brandon TG. et al Comparative Effectiveness of Tumor Necrosis Factor Agents and Disease-modifying Antirheumatic Therapy in Children with Enthesitis-related Arthritis: The First Year after Diagnosis. J Rheumatol 2018; 45: 107-114
    CrossrefPubMedSearch in Google Scholar
  • 10 Zisman D, Stoll ML, Butbul Aviel Y. et al Juvenile Psoriatic Arthritis: A Report from the GRAPPA 2017 Annual Meeting. J Rheumatol Suppl 2018; 94: 11-16
    CrossrefPubMedSearch in Google Scholar
  • 11 Brunner HI, Ivaskova E, Haas JP. et al Class I associations and frequencies of class II HLA-DRB alleles by RFLP analysis in children with rheumatoid-factor-negative juvenile chronic arthritis. Rheumatol Int 1993; 13: 83-88
    CrossrefPubMedSearch in Google Scholar
  • 12 Hall PJ, Burman SJ, Barash J. et al HLA and complement C4 antigens in polyarticular onset seronegative juvenile chronic arthritis: association of early onset with HLA-DRw8. J Rheumatol 1989; 16: 55-59
    PubMedSearch in Google Scholar
  • 13 Oen K, Malleson PN, Cabral DA. et al Early predictors of longterm outcome in patients with juvenile rheumatoid arthritis: subset-specific correlations. J Rheumatol 2003; 30: 585-593
    PubMedSearch in Google Scholar
  • 14 Hameed K, Bowman S, Kondeatis E. et al The association of HLA-DRB genes and the shared epitope with rheumatoid arthritis in Pakistan. Br J Rheumatol 1997; 36: 1184-1188
    CrossrefPubMedSearch in Google Scholar
  • 15 Haas JP, Andreas A, Rutkowski B. et al A model for the role of HLA-DQ molecules in the pathogenesis of juvenile chronic arthritis. Rheumatol Int 1991; 11: 191-197
    CrossrefPubMedSearch in Google Scholar
  • 16 Haas JP, Kimura A, Truckenbrodt H. et al Early-onset pauciarticular juvenile chronic arthritis is associated with a mutation in the Y-box of the HLA-DQA1 promoter. Tissue Antigens 1995; 45: 317-321
    CrossrefPubMedSearch in Google Scholar
  • 17 Haas JP, Metzler M, Frank C. et al HLA-DQA1 gene expression profiling in oligoarticular JIA. Autoimmunity 2009; 42: 389-391
    CrossrefPubMedSearch in Google Scholar
  • 18 Hinks A, Cobb J, Marion MC. et al Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. Nat Genet 2013; 45: 664-669
    CrossrefPubMedSearch in Google Scholar
  • 19 Eyre S, Bowes J, Diogo D. et al High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 2012; 44: 1336-1340
    CrossrefPubMedSearch in Google Scholar
  • 20 Hinks A, Marion MC, Cobb J. et al Brief Report: The Genetic Profile of Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis Resembles That of Adult Rheumatoid Arthritis. Arthritis Rheumatol 2018; 70: 957-962
    CrossrefPubMedSearch in Google Scholar
  • 21 Haas JP, Weimann V, Feist E. [Polyarticular juvenile idiopathic arthritis and rheumatoid arthritis : Common features and differences]. Z Rheumatol 2022; 81: 4-13
    CrossrefPubMedSearch in Google Scholar
  • 22 Rabionet R, Remesal A, Mensa-Vilaro A. et al Biallelic loss-of-function LACC1/FAMIN Mutations Presenting as Rheumatoid Factor-Negative Polyarticular Juvenile Idiopathic Arthritis. Sci Rep 2019; 09: 4579
    CrossrefPubMedSearch in Google Scholar
  • 23 Dueckers G, Guellac N, Arbogast M. et al Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 2012; 142: 176-193
    CrossrefPubMedSearch in Google Scholar
  • 24 Lucas P, Bodemer C, Barbarot S. et al Methotrexate in Severe Childhood Alopecia Areata: Long-term Follow-up. Acta Derm Venereol 2016; 96: 102-103
    CrossrefPubMedSearch in Google Scholar
  • 25 Truckenbrodt H, Hafner R. Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study. Arthritis Rheum 1986; 29: 801-807
    CrossrefPubMedSearch in Google Scholar
  • 26 Huang B, Qiu T, Chen C. et al Timing matters: real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis. RMD Open 2020: 6
    PubMedSearch in Google Scholar
  • 27 Minden K, Horneff G, Niewerth M. et al Time of Disease-Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug-Free Remission in Young Adulthood. Arthritis Care Res (Hoboken) 2019; 71: 471-481
    CrossrefPubMedSearch in Google Scholar
  • 28 Wallace CA, Giannini EH, Spalding SJ. et al Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. J Rheumatol 2014; 41: 1163-1170
    CrossrefPubMedSearch in Google Scholar
  • 29 Ravelli A, Consolaro A, Horneff G. et al Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis 2018; 77: 819-828
    PubMedSearch in Google Scholar
  • 30 Oommen PT, Schütz K, Baltruschat K. et al S2k-Leitlinie „Therapie der Juvenilen Idiopathischen Arthritis“ (2019). Im Internet. www.awmf.org/leitlinien/aktuelle-leitlinien.html Stand: 02.10.2020
  • 31 Horneff G, Klein A, Ganser G. et al Protocols on classification, monitoring and therapy in children’s rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2017; 15: 78
    CrossrefPubMedSearch in Google Scholar
  • 32 Lim LSH, Lokku A, Pullenayegum E. et al Probability of Response in the First Sixteen Weeks After Starting Biologics: An Analysis of Juvenile Idiopathic Arthritis Biologics Trials. Arthritis Care Res (Hoboken) 2023; 75: 1238-1249
    CrossrefPubMedSearch in Google Scholar
  • 33 Wallace CA, Giannini EH, Huang B. et al American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011; 63: 929-936
    CrossrefPubMedSearch in Google Scholar
  • 34 Consolaro A, Ruperto N, Bazso A. et al Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009; 61: 658-666
    CrossrefPubMedSearch in Google Scholar
  • 35 Consolaro A, Ruperto N, Bracciolini G. et al Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score. Ann Rheum Dis 2014; 73: 1380-1383
    CrossrefPubMedSearch in Google Scholar
  • 36 Singh G, Athreya BH, Fries JF. et al Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994; 37: 1761-1769
    CrossrefPubMedSearch in Google Scholar
  • 37 Merker J, Hartmann M, Haas JP. et al Combined three-dimensional gait and plantar pressure analyses detecting significant functional deficits in children with juvenile idiopathic arthritis. Gait & posture 2018; 66: 247-254
    CrossrefPubMedSearch in Google Scholar
  • 38 Consolaro A, Bracciolini G, Ruperto N. et al Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum 2012; 64: 2366-2374
    CrossrefPubMedSearch in Google Scholar
  • 39 Brinster A, Guillot X, Prati C. et al Evolution over thirty years of the profile of inpatients with reactive arthritis in a tertiary rheumatology unit. Reumatol Clin (Engl Ed) 2018; 14: 36-39
    CrossrefPubMedSearch in Google Scholar
  • 40 Furness L, Riley P, Wright N. et al Monogenic disorders as mimics of juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2022; 20: 44
    CrossrefPubMedSearch in Google Scholar
  • 41 Genovese G, Moltrasio C, Garcovich S. et al PAPA spectrum disorders. G Ital Dermatol Venereol 2020; 155: 542-550
    CrossrefPubMedSearch in Google Scholar
  • 42 Gunes A, Akin A, Ture M. et al Evaluation of Children with Acute Rheumatic Fever: A Single-Center Experience. Turk Arch Pediatr 2022; 57: 26-31
    CrossrefPubMedSearch in Google Scholar
  • 43 Haas JP. Vaskulitiden des Kindes- und Jugendalters. Pädiatrische Praxis 2022; 98: 1-19
    Search in Google Scholar
  • 44 Häfner R, Haas JP. Arthropathien bei Kindern und Jugendlichen als Folge genetischer Erkrankungen. Akt Rheumatologie 2016; 41: 396-404
    Search in Google Scholar
  • 45 Horneff G. Juveniler systemischer Lupus erythematodes. päd Praxis 2023; 100: 110-130
    Search in Google Scholar
  • 46 Huang XF, Brown MA. Progress in the genetics of uveitis. Genes Immun 2022; 23: 57-65
    CrossrefPubMedSearch in Google Scholar
  • 47 Lampe C, Scarpa M, Bellettato CM. et al Milde Mukopolysaccharidose-Formen [Mild Forms of Mucopolysaccharidosis]. Akt Rheumatol 2016; 41: 383-389
    Thieme ConnectSearch in Google Scholar
  • 48 Nikolic RPA, Moran Toro C. Childhood-Onset COPA Syndrome Recognized Retrospectively in the Context of Polyarticular Juvenile Idiopathic Arthritis and Rheumatoid Arthritis. Case Rep Rheumatol 2023; 2023: 3240245
    PubMedSearch in Google Scholar
  • 49 Solyom A, Hügle B, Beck M. et al Morbus Farber: eine Ursache der Arthritis im Kindesalter [Farber Disease: A Cause of Arthritis in Childhood]. Akt Rheumatol 2016; 41: 372-376
    Thieme ConnectSearch in Google Scholar
  • 50 Oen K, Malleson PN, Cabral DA. et al Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002; 29: 1989-1999
    PubMedSearch in Google Scholar
  • 51 Kallinich T, Hinze C, Wittkowski H. [Classification of autoinflammatory diseases based on pathophysiological mechanisms]. Z Rheumatol 2020; 79: 624-638
    PubMedSearch in Google Scholar
  • 52 Rubbert-Roth A. [Differential diagnosis of polyarthritis]. Deutsche medizinische Wochenschrift 2015; 140: 1125-1130
    PubMedSearch in Google Scholar
  • 53 Murias S, Magallares L, Albizuri F. et al Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics. Ther Drug Monit 2017; 39: 370-378
    CrossrefPubMedSearch in Google Scholar
  • 54 Rodriguez-Baez AS, Huerta-Garcia AP, Medellin-Garibay SE. et al Disease activity and therapeutic drug monitoring of polyglutamates of methotrexate after daily or weekly administration of low-dose methotrexate in patients recently diagnosed with rheumatoid arthritis. Basic Clin Pharmacol Toxicol 2022; 130: 644-654
    CrossrefPubMedSearch in Google Scholar
  • 55 De Klerk E, Van Der Heijde D, Landewé R. et al The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study. J Rheumatol 2003; 30: 2469-2475
    PubMedSearch in Google Scholar
  • 56 Hebing RC, Aksu I, Twisk JW. et al Effectiveness of electronic drug monitoring feedback to increase adherence in patients with RA initiating a biological DMARD: a randomised clinical trial. RMD. 2022 Open 8
    PubMedSearch in Google Scholar
  • 57 Santer M, Ring N, Yardley L. et al Treatment non-adherence in pediatric long-term medical conditions: systematic review and synthesis of qualitative studies of caregivers’ views. BMC Pediatr 2014; 14: 63
    CrossrefPubMedSearch in Google Scholar
  • 58 Brüning T, Oberle A, Mohr C. et al Kinderschutz bei Kindern und Jugendlichen mit chronischen Erkrankungen. Monatsschr Kinderheilkd 2022; 170: 716-721
    CrossrefSearch in Google Scholar
  • 59 Wolfs JF, Arts MP, Peul WC. Juvenile chronic arthritis and the craniovertebral junction in the paediatric patient: review of the literature and management considerations. Adv Tech Stand Neurosurg 2014; 41: 143-156
    CrossrefPubMedSearch in Google Scholar
  • 60 Stoustrup P, Resnick CM, Abramowicz S. et al Management of Orofacial Manifestations of Juvenile Idiopathic Arthritis: Interdisciplinary Consensus-Based Recommendations. Arthritis Rheumatol 2023; 75: 4-14
    CrossrefPubMedSearch in Google Scholar
  • 61 Bovid KM, Moore MD. Juvenile Idiopathic Arthritis for the Pediatric Orthopedic Surgeon. Orthop Clin North Am 2019; 50: 471-488
    CrossrefPubMedSearch in Google Scholar
  • 62 Rongo R, Michelotti A, Pedersen TK. et al Management of temporomandibular joint arthritis in children and adolescents: An introduction for orthodontists. Orthod Craniofac Res. 2023 May 2024
    CrossrefSearch in Google Scholar
  • 63 Rubin S, Ohana O, Goldberg O. et al The efficacy and safety of intra-articular injection of triamcinolone acetonide versus triamcinolone hexacetonide for treatment of juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2022; 20: 5
    CrossrefPubMedSearch in Google Scholar
  • 64 Arbogast M, Haas JP. [Treatment options in juvenile idiopathic arthritis – Part 2: Orthopedics und surgery]. Orthopade 2018; 47: 917-925
    Search in Google Scholar
  • 65 Haas JP, Arbogast M. [Therapeutic options in juvenile idiopathic arthritis : Surgical and conservative orthopedic rheumatological treatment]. Z Rheumatol 2021; 80: 467-480
    CrossrefPubMedSearch in Google Scholar
  • 66 Buttgereit F, Doering G, Schaeffler A. et al Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008; 371: 205-214
    CrossrefPubMedSearch in Google Scholar
  • 67 Ruperto N, Brunner HI, Synoverska O. et al Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet 2021; 398: 1984-1996
    CrossrefPubMedSearch in Google Scholar
  • 68 Ruperto N, Brunner HI, Zuber Z. et al Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatr Rheumatol Online J 2017; 15: 86
    CrossrefPubMedSearch in Google Scholar
  • 69 Carmichael SJ, Beal J, Day RO. et al Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J Rheumatol 2002; 29: 2077-2083
    PubMedSearch in Google Scholar
  • 70 Ramanan AV, Quartier P, Okamoto N. et al Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial. Lancet 2023; 402: 555-570
    CrossrefPubMedSearch in Google Scholar
  • 71 Kuek A, Hazleman BL, Gaston JH. et al Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab. Rheumatology (Oxford) 2006; 45: 1448-1449
    CrossrefPubMedSearch in Google Scholar
  • 72 Sakamoto AP, Pinheiro MM, Barbosa CM. et al Rituximab use in young adults diagnosed with juvenile idiopathic arthritis unresponsive to conventional treatment: report of 6 cases. Rev Bras Reumatol 2015; 55: 536-541
    PubMedSearch in Google Scholar
  • 73 Wallace CA, Ruperto N, Giannini E. et al Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004; 31: 2290-2294
    PubMedSearch in Google Scholar
  • 74 Hartmann M, Kreuzpointner F, Haefner R. et al Effects of juvenile idiopathic arthritis on kinematics and kinetics of the lower extremities call for consequences in physical activities recommendations. Int J Pediatr 2010; 2010: 835984
    CrossrefPubMedSearch in Google Scholar
  • 75 Barth S, Haas JP, Schlichtiger J. et al Long-Term Health-Related Quality of Life in German Patients with Juvenile Idiopathic Arthritis in Comparison to German General Population. PLoS One 2016; 11: e0153267
    CrossrefPubMedSearch in Google Scholar
  • 76 Hartmann M, Kreuzpointner F, Schrödl S. et al Sport bei rheumatischen Erkrankungen im Kindes- und Jugendalter. Akt Rheumatol 2012; 37: 154-160
    Thieme ConnectSearch in Google Scholar
  • 77 Hartmann M, Merker J, Schrodl S. et al [Back to school physical education despite rheumatism : Development and testing of a sport scientific-based physical education certification]. Z Rheumatol 2018; 77: 651-666
    PubMedSearch in Google Scholar
  • 78 Spamer M, Georgi M, Hafner R. et al [Physiotherapy for juvenile idiopathic arthritis]. Z Rheumatol 2012; 71: 387-395
    CrossrefPubMedSearch in Google Scholar